New hope for esophageal cancer: drug-radiation combo targets tough cases
NCT ID NCT07188103
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tests a new drug called ivonescimab combined with a short course of radiation for people with advanced esophageal cancer that has gotten worse after initial treatment. The goal is to see if this combination can slow the cancer's growth and improve survival. The study will enroll 37 adults and track their progress over two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincal Hospital
RECRUITINGHefei, Anhui, 230000, China
Conditions
Explore the condition pages connected to this study.